Electronic Resource
Oxford, UK
:
Blackwell Publishing Ltd
The @breast journal
3 (1997), S. 0
ISSN:
1524-4741
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
Abstract: The need for breast cancer chemoprevention is introduced. Evidence for chemopreventive activity has been provided by a decrease in the prevalence of contralateral breast cancer in large adjuvant trials of tamoxifen or fenretinide versus placebo. The NSABP tamoxifen prevention trial in high-risk women is nearing completion. Before other large phase III trials are initiated, phase II trials should be conducted using morphologic and molecular markers as indicators of response (surrogate endpoint biomarkers). Phase II models currently utilized include: (a) a short-interval trial between biopsy and re-excision in women with DCIS; and (b) a longer interval trial in which high-risk women with epithelial hyperplasia and atypia noted on random fine-needle aspiration receive drug or placebo for 6 months and are then reaspirated. Strengths and weaknesses of both models used in ongoing phase II trials are discussed.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1111/j.1524-4741.1997.tb00175.x
Permalink
Library |
Location |
Call Number |
Volume/Issue/Year |
Availability |